抗体阴性自身免疫性脑炎的长期结局:一项回顾性研究
该回顾性研究纳入45例「仅可能」或「很可能但抗体阴性」的自身免疫性脑炎成人患者,中位随访36个月。多数患者基线存在显著残疾,接受免疫治疗后98%至少部分改善,但31%出现临床复发,69%遗留记忆障碍。3个月时mRS评分较高和需要步态辅助可预测不良结局。
要点
- 抗体阴性但临床疑似自身免疫性脑炎的患者,尽管初期残疾显著,免疫治疗仍有改善潜力。
- 3个月时mRS评分较高和需要步态辅助可预测长期不良结局(P≤0.01)。
核心结论
- 抗体阴性但临床疑似自身免疫性脑炎的患者尽管初期残疾显著,免疫治疗仍显示改善潜力,强调早期干预的重要性。
- 早期功能状态和步态辅助需求可能有助于预测长期预后。
研究设计与样本
- 回顾性分析2006年至2020年在一家三级中心神经免疫门诊评估的成人患者,符合「仅可能」或「很可能但抗体阴性」自身免疫性脑炎诊断标准,随访至少1年。
- 共纳入45例患者,中位年龄61岁(范围20-88),女性21例(47%),中位随访36个月(范围12-174)。
- 所有患者均接受神经抗体检测。
主要发现
- 基线时41/45(91%)存在显著残疾(mRS≥3)。
- 脑脊液炎症20/44(45%),MRI异常21/45(47%),组织法检测到未分类神经特异性IgG染色5例(11%),副肿瘤病因2例(4%)。
- 从起病到启动免疫治疗的中位时间为2个月(范围0-21),44例(98%)接受治疗者均至少部分改善。
- 临床复发14/45(31%);末次随访时最常见症状为记忆障碍31/45(69%)、注意力缺陷17/45(38%)、步态不稳13/45(29%)、视空间功能障碍10/45(22%)。
- 末次随访中位mRS为2(范围0-6),11例神经功能结局不良(mRS≥3);3个月时mRS评分较高和需要步态辅助预测不良结局(P≤0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize the long-term outcomes of patients with "possible only" or "probable" autoimmune encephalitis (AE). BACKGROUND: Despite comprising one-third of AE cases, antibody-negative cases lacking typical AE-defining features are understudied. DESIGN/METHODS: We conducted a retrospective analysis of adult patients evaluated at a tertiary center neuroimmunology practice from 2006 to 2020, meeting diagnostic criteria for "possible only" or "probable but antibody-negative" AE, with at least one year of follow-up. All patients underwent neural antibody testing. RESULTS: Forty-five patients (median age, 61 years [range, 20-88]; female, 21 [47%]) were included, with a median follow-up of 36 months (range, 12-174). A change in diagnosis was noted in six additional patients, who were excluded from further analysis, with only two receiving a non-autoimmune diagnosis during follow-up. The majority (41/45 [91%]) presented with significant disability (modified Rankin Scale [mRS] ≥3) at baseline. CSF was inflammatory in 20/44 (45%) and MRI was abnormal in 21/45 (47%). Unclassified neural-specific IgG staining on tissue-based assay was detected in five (11%). Two cases (4%) had a paraneoplastic cause. The median time from onset to immunotherapy initiation was two months (range, 0-21), resulting in at least partial improvement in all 44 (98%) treated cases. Clinical relapses occurred in 14/45 (31%). At last follow-up, the most common symptoms were memory dysfunction (31/45 [69%]), attention deficits (17/45 [38%]), gait instability (13/45 [29%]), and visuospatial dysfunction (10/45 [22%]). Most patients achieved independence (median mRS, 2 [range, 0-6]); however, 11 patients had poor neurological outcome (mRS ≥3). Higher mRS score and gait assistance requirement at three months were predictive of poor outcome (P ≤0.01). CONCLUSIONS: Despite significant disability at initial stages, patients with antibody-negative but clinically presumed AE show potential for improvement with immunotherapy, highlighting the importance of early intervention. Early functional status and gait assistance requirements may assist in predicting long-term prognosis.
引用
- Mangioris G, Orozco E, Dubey D, et al. Long-Term Outcomes in Antibody-Negative Autoimmune Encephalitis: A Retrospective Study. Neurology. 2024. PMID: 39378382. doi:10.1212/01.wnl.0001051560.74390.09
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。